Inventor · disambiguated record
Rebecca M. Lui
Also filed as: LUI REBECCA · LUI REBECCA M
41 granted patents·10 pending applications·138 citations·filing 2013–2025
97Inventor score
Files withCHEMOCENTRYX INC51
Top patents by PatentIndex Score
51 records- 0196US11713307B2Heteroaryl-biphenyl amides for the treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Aug 1, 2023·8 cites·28 claims
- 0296US11026935B2Free base crystalline form of a complement component C5a receptorCHEMOCENTRYX INC·Filed 2020·Granted Jun 8, 2021·5 cites·9 claims
- 0396US10562896B26-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Feb 18, 2020·11 cites·38 claims
- 0495US9783540B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2016·Granted Oct 10, 2017·7 cites·45 claims
- 0594US10683294B25-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Jun 16, 2020·8 cites·31 claims
- 0694US10464934B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2017·Granted Nov 5, 2019·5 cites·13 claims
- 0794US9745268B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Aug 29, 2017·11 cites·31 claims
- 0893US11479553B25-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Oct 25, 2022·3 cites·24 claims
- 0993US11384079B26-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2019·Granted Jul 12, 2022·5 cites·18 claims
- 1093US10266492B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2017·Granted Apr 23, 2019·8 cites·10 claims
- 1192US11485737B2Diaryl substituted 5,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Nov 1, 2022·2 cites·29 claims
- 1292US9169261B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2013·Granted Oct 27, 2015·13 cites·26 claims
- 1391US11059825B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Jul 13, 2021·2 cites·11 claims
- 1491US8916601B2Aza-aryl 1H-pyrazol-1-YL benzene sulfonamidesCHEMOCENTRYX INC·Filed 2013·Granted Dec 23, 2014·12 cites·20 claims
- 1590US10759807B2Diaryl substituted 5,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Sep 1, 2020·7 cites·38 claims
- 1689US10759789B22-oxindole compoundsCHEMOCENTRYX INC·Filed 2019·Granted Sep 1, 2020·2 cites·27 claims
- 1789US10532982B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Jan 14, 2020·4 cites·1 claims
- 1889US10421748B22-oxindole compoundsCHEMOCENTRYX INC·Filed 2018·Granted Sep 24, 2019·3 cites·43 claims
- 1987US11427541B2Salt forms of a complement component C5A receptorCHEMOCENTRYX INC·Filed 2020·Granted Aug 30, 2022·2 cites·32 claims
- 2086US11434230B22-oxindole compoundsCHEMOCENTRYX INC·Filed 2020·Granted Sep 6, 2022·1 cites·14 claims
- 2186US9783544B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Oct 10, 2017·4 cites·26 claims
- 2285US10596163B2Aza-aryl 1H-pyrazol-1-yl benzene sulfonamidesCHEMOCENTRYX INC·Filed 2018·Granted Mar 24, 2020·3 cites·19 claims
- 2383US12139475B22-oxindole compoundsCHEMOCENTRYX INC·Filed 2022·Granted Nov 12, 2024·0 cites·4 claims
- 2483US11603356B2Amorphous form of a complement component C5a receptorCHEMOCENTRYX INC·Filed 2020·Granted Mar 14, 2023·1 cites·43 claims
- 2581US9340509B2CCR6 compoundsCHEMOCENTRYX INC·Filed 2014·Granted May 17, 2016·4 cites·17 claims
- 2680US12371433B2Heteroaryl-biphenyl amines for the treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2023·Granted Jul 29, 2025·0 cites·13 claims
- 2780US10137120B2Aza-aryl 1H-pyrazol-1-yl benzene sulfonamidesCHEMOCENTRYX INC·Filed 2014·Granted Nov 27, 2018·2 cites·19 claims
- 2880US9795599B2CCR6 compoundsCHEMOCENTRYX INC·Filed 2016·Granted Oct 24, 2017·2 cites·24 claims
- 2979US11845729B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2022·Granted Dec 19, 2023·0 cites·10 claims
- 3079US2025346598A1Heteroaryl-biphenyl amines for the treatment of pd-l1 diseasesCHEMOCENTRYX INC·Filed 2025·Application pending·0 cites
- 3178US11834452B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2021·Granted Dec 5, 2023·0 cites·14 claims
- 3278US10287292B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2017·Granted May 14, 2019·1 cites·7 claims
- 3378US10117865B2CCR6 compoundsCHEMOCENTRYX INC·Filed 2017·Granted Nov 6, 2018·1 cites·6 claims
- 3477US2023381167A1FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTORCHEMOCENTRYX INC·Filed 2023·Application pending·0 cites
- 3576US2022047575A1Aza-aryl 1h-pyrazol-1-yl benzene sulfonamidesCHEMOCENTRYX INC·Filed 2021·Application pending·0 cites
- 3675US11773091B26-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2022·Granted Oct 3, 2023·0 cites·20 claims
- 3774US12497383B2Heteroaryl-biphenyl amides for the treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2023·Granted Dec 16, 2025·0 cites·20 claims
- 3874US12054484B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2021·Granted Aug 6, 2024·0 cites·8 claims
- 3973US10786494B2CCR6 compoundsCHEMOCENTRYX INC·Filed 2018·Granted Sep 29, 2020·0 cites·5 claims
- 4072US11608336B2Prodrugs of fused-bicyclic C5aR antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Mar 21, 2023·1 cites·43 claims
- 4172US2020354320A1PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTSCHEMOCENTRYX INC·Filed 2019·Application pending·0 cites
- 4271US11807609B2Deuterated compounds as immunomodulatorsCHEMOCENTRYX INC·Filed 2020·Granted Nov 7, 2023·0 cites·2 claims
- 4370US2020121688A1Substituted tetrahydropyrans as ccr2 modulatorsCHEMOCENTRYX INC·Filed 2019·Application pending·0 cites
- 4468US11866429B2Heteroaryl-biphenyl amines for the treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Jan 9, 2024·0 cites·26 claims
- 4568US2020197386A1Aza-Aryl 1H-Pyrazol-yl Benzene SulfonamidesCHEMOCENTRYX INC·Filed 2020·Application pending·0 cites
- 4668US2022096453A1FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTORCHEMOCENTRYX INC·Filed 2021·Application pending·0 cites
- 4763US2023382894A1Ccr4 antagonistsCHEMOCENTRYX INC·Filed 2023·Application pending·0 cites
- 4862US2019144389A1Deuterated compounds as immunomodulatorsCHEMOCENTRYX INC·Filed 2018·Application pending·0 cites
- 4962US2017204087A12-oxindole compoundsCHEMOCENTRYX INC·Filed 2017·Application pending·0 cites
- 5060US12448373B2Azetidinyl-acetamides as CXCR7 inhibitorsCHEMOCENTRYX INC·Filed 2022·Granted Oct 21, 2025·0 cites·30 claims
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Rebecca M. Lui files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →